Monopar TherapeuticsMNPREarnings & Financial Report
Nasdaq
MNPR Q2 2024 Key Financial Metrics
Revenue
$73.5K
Gross Profit
N/A
Operating Profit
$-1.8M
Net Profit
$-1.7M
Gross Margin
N/A
Operating Margin
-2434.5%
Net Margin
-2334.5%
YoY Growth
-42.7%
EPS
$-0.10
Financial Flow
Monopar Therapeutics Q2 2024 Financial Summary
Monopar Therapeutics reported revenue of $73.5K for Q2 2024, with a net profit of $-1.7M (-2334.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $73.5K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | N/A |
| Operating Margin | -2434.5% |
| Report Period | Q2 2024 |
Monopar Therapeutics Annual Revenue by Year
Monopar Therapeutics annual revenue history includes year-by-year totals (for example, 2023 revenue was $429.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $429.0K |
| 2022 | $21.2K |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7698 | $12660 | $90488 | $128218 | $112260 | $98073 | $82165 | $73475 |
| YoY Growth | 1234.1% | 2311.4% | 19401.7% | 30647.7% | 1358.3% | 674.7% | -9.2% | -42.7% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.4M | $13.2M | $11.8M | $10.3M | $8.6M | $7.3M | $8.9M | $7.2M |
| Liabilities | $1.9M | $3.1M | $2.9M | $2.5M | $2.0M | $1.8M | $1.4M | $1.1M |
| Equity | $12.5M | $10.1M | $8.9M | $7.8M | $6.6M | $5.6M | $7.5M | $6.1M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.1M | $-1.3M | $-2.3M | $-2.1M | $-1.9M | $-1.5M | $-1.7M | $-1.7M |